Most Read

Fedratinib is a highly selective JAK2 inhibitor intended for the treatment of patients with myelofibrosis, a serious bone marrow disorder that disrupts the body’s normal production of blood

The data, part of a broader ongoing 52 week Phase III study in 543 patients, show 97.7% of patients treated with Cosentyx 300mg achieved PASI 75 and 80.9%

The collaboration leverages Abpro’s proprietary DiversImmuneTM antibody discovery platform. Under  the  terms  of  the  agreement,  Abpro  is  eligible to  receive up  to  $4  billion,  including $60 million  in 

Financial terms of the transaction have not been disclosed. The manufacturing site, which is approved for manufacturing of both small molecule and biologic products, is the first FDA-approved

This new treatment includes the same monoclonal antibody as intravenous Herceptin® (trastuzumab) in combination with recombinant human hyaluronidase PH20, an enzyme that helps to deliver trastuzumab under the

The study met its primary endpoint, showing more patients treated with teprotumumab compared with placebo had a meaningful improvement in proptosis, or bulging of the eye: 82.9 percent

The approval allows Nuformix to initiate the first dosing of NXP001 in an open-label study to compare the bioavailability of NXP001 to Merck’s EMEND  in healthy subjects. Nuformix

New investor Seventure Partners, via its microbiome-focused fund Health for Life Capital™, led the financing along with existing investors Longwood Fund, Domain Associates, Heritage Medical Systems and a

“As we continue to transform Bausch Health, we are now pivoting to offense with research investments and strategic acquisitions that augment our core businesses. We are excited to